CMN Weekly (8 November 2024) - Your Weekly CRISPR...
CMN Weekly
Nov. 8, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Cellectis
Main focus: Next generation allogeneic CAR-T cell therapies
Company stage: Clinical
Diseases: acute myeloid leukaemia, B-cell acute lymphoblastic leukaemia (B-ALL), multiple myeloma, Non-Hodgkin's lymphoma
Genome editing technology: TALEN
Funding stage: Public (NASDAQ:CLLS)
Location: Paris, France and New York, USA
Website: https://www.cellectis.com/en
Pipeline: https://www.cellectis.com/en/products/product-candidates/
Partners: Allogene Therapeutics, Servier Biopharmaceuticals, Iovance Biotherapeutics, Cytovia Therapeutics
Cellectis develops next generation allogeneic CAR-T cell therapies using its proprietary Transcription activator-like effector nuclease (TALEN) technology. The company has multiple clinical assets currently in Phase 1/2 dose escalation and dose expansion studies. The initial focus is on different types of haematological cancers, such as Non-Hodgkin's lymphoma and leukaemia. The company has licensed the TALEN technology to multiple other companies working with cellular therapies.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT04150497)
Sponsors:
Cellectis S.A.
Sponsors:
Cellectis S.A.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
